title: MicroRNA-181a enhances the chemotherapeutic sensitivity of chronic myeloid leukemia to imatinib.
abstract: MicroRNA-181 (miR-181) has been recently demonstrated to participate in the differentiation and development of immune cells, including natural killer cells and B and T lymphocytes, and myeloid linages, including erythroid and megakaryocytic cells. The aberrant expression of miR-181, particularly low expression levels, has been observed in a number of leukemia types, including B-cell chronic lymphocytic leukemia and cytogenetically abnormal acute myeloid leukemia. However, the expression and function of miR-181 in chronic myeloid leukemia (CML) remains unknown. In the present study, the aberrant expression of miR-181a was analyzed in a patient with CML and in the CML K562 cell line. In addition, the function and potential mechanisms of miR-181a in K562 cells with regard to their chemotherapeutic sensitivity to imatinib were investigated. The expression levels of miR-181a were significantly reduced in the patient with CML and in the CML K562 cell line. Furthermore, the overexpression of miR-181a in the K562 cells enhanced the chemotherapeutic sensitivity of these cells to imatinib. The potential mechanism mediating these effects may be associated with the capacity of miR-181a to inhibit cell growth and/or to induce cells apoptosis and differentiation in K562 cells. The results of the present study suggested that miR-181a may be a target for the treatment of CML and a useful indicator of the therapeutic sensitivity of CML to imatinib.
authors.affiliation: Department of Gastrointestinal Medical Oncology, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China.
authors.forename: Guangyu
authors.initials: G
authors.lastname: Wang
authors.affiliation: Department of Pathology, Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China.
authors.forename: Ran
authors.initials: R
authors.lastname: Zhao
authors.affiliation: Department of Cardiovascular, Inner Mongolia People's Hospital, Hohhot, Inner Mongolia 010070, P.R. China.
authors.forename: Xingsheng
authors.initials: X
authors.lastname: Zhao
authors.affiliation: Department of Hematology, The Second Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China.
authors.forename: X I
authors.initials: XI
authors.lastname: Chen
authors.affiliation: Department of Oncology and Hematology, Inner Mongolia Tongliao City Hospital, Tongliao, Inner Mongolia 028000, P.R. China.
authors.forename: Dong
authors.initials: D
authors.lastname: Wang
authors.affiliation: Department of Pathology, Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China.
authors.forename: Yinji
authors.initials: Y
authors.lastname: Jin
authors.affiliation: Department of Cardiovascular, Inner Mongolia People's Hospital, Hohhot, Inner Mongolia 010070, P.R. China.
authors.forename: X I
authors.initials: XI
authors.lastname: Liu
authors.affiliation: Department of Gastrointestinal Medical Oncology, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China.
authors.forename: C I
authors.initials: CI
authors.lastname: Zhao
authors.affiliation: Department of Gastrointestinal Medical Oncology, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China.
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Zhu
authors.affiliation: Department of Obstetrics and Gynecology, The First Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China.
authors.forename: Chengcheng
authors.initials: C
authors.lastname: Ren
authors.affiliation: Department of Cardiovascular, Inner Mongolia People's Hospital, Hohhot, Inner Mongolia 010070, P.R. China.
authors.forename: Minghui
authors.initials: M
authors.lastname: Li
authors.affiliation: Department of Pathology, Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China.
authors.forename: Xiaoming
authors.initials: X
authors.lastname: Jin
authors.affiliation: Department of Microbiology, Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China.
authors.forename: Fengmin
authors.initials: F
authors.lastname: Zhang
authors.affiliation: Department of Microbiology, Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China.
authors.forename: Zhaohua
authors.initials: Z
authors.lastname: Zhong
authors.affiliation: Department of Pathology, Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China.
authors.forename: Tianzhen
authors.initials: T
authors.lastname: Wang
authors.affiliation: Department of Pathology, Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China ; Translational Medicine Center of Northern China, Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China ; Basic Medical Institute, Heilongjiang Medical Science Academy, Harbin, Heilongjiang 150086, P.R. China.
authors.forename: Xiaobo
authors.initials: X
authors.lastname: Li
keywords: chemotherapeutic sensitivity; chronic myeloid leukemia; microRNA-181a